The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

Creative Commons License

Turk C., OKAY M., TÜRK S., Temirci E. S., Javad O., AKSU S., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.2, ss.661-674, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 49 Sayı: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.3906/sag-1807-152
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.661-674
  • Anahtar Kelimeler: Lymphoma, ruxolitinib, JAK/STAT signaling pathway, B-CELL LYMPHOMA, CD30 EXPRESSION, RETROSPECTIVE ANALYSIS, CD20, PATHOGENESIS, PROGNOSIS, RITUXIMAB, PATHWAY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background/aim: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition in myelofibrosis is associated with an elevated frequency of aggressive B-cell lymphomas. However, the biological basis and significance of this pharmacobiological adverse event is unknown. The aim of this bioinformatics study is to detect any possible confounding effects of ruxolitinib on the genesis of lymphoproliferative disorders.